TY -的T1 dasatinib-ind的长期结果uced pulmonary arterial hypertension: a population-based study JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00217-2017 VL - 50 IS - 1 SP - 1700217 AU - Weatherald, Jason AU - Chaumais, Marie-Camille AU - Savale, Laurent AU - Jaïs, Xavier AU - Seferian, Andrei AU - Canuet, Matthieu AU - Bouvaist, Hélène AU - Magro, Pascal AU - Bergeron, Anne AU - Guignabert, Christophe AU - Sitbon, Olivier AU - Simonneau, Gérald AU - Humbert, Marc AU - Montani, David Y1 - 2017/07/01 UR - //www.qdcxjkg.com/content/50/1/1700217.abstract N2 - This study aimed to describe the long-term outcomes of pulmonary arterial hypertension (PAH) induced by dasatinib.21 incident, right heart catheterisation-confirmed cases of dasatinib-induced PAH were identified from the French Pulmonary Hypertension Registry. Clinical and haemodynamic variables were compared from baseline to last follow-up (median (range) 24 (1–81) months).Median age was 52 years and 15 patients were female (71%). 19 patients received dasatinib for chronic myelogenous leukaemia for a median (range) duration of 42 (8–74) months before PAH diagnosis. No bone morphogenic protein receptor-2 (BMPR2) mutations were found in the 10 patients tested. Dasatinib was uniformly discontinued and 11 patients received PAH medications. Four patients died during follow-up. New York Heart Association functional class improved from 76% in class III/IV to 90% in class I/II (p<0.01). Median (range) 6-min walk distance improved from 306 (0–660) to 430 (165–635) m (p<0.01). Median (range) mean pulmonary arterial pressure improved from 45 (30–70) to 26 (17–50) mmHg (p<0.01) and pulmonary vascular resistance from 6.1 (3.2–27.3) to 2.6 (1.2–5.9) Wood units (p<0.01). Patients treated with PAH medications had worse baseline haemodynamics but similar long-term outcomes to untreated patients. PAH persisted in 37% of patients.Dasatinib-induced PAH frequently improves after discontinuation but persisted in over one-third of patients, therefore systematic follow-up is essential.Dasatinib-induced pulmonary arterial hypertension persists in over one-third of patients despite stopping dasatinib http://ow.ly/xRPt30csyk9 ER -